Trulicity 4.5 mg is available as a prescription medication for type 2 diabetes. It is administered through subcutaneous injection. The dosage and availability can vary based on specific healthcare provider recommendations and pharmacy stock.
What is Trulicity Used For?
Trulicity (dulaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It is prescribed to improve glycemic control in adults with type 2 diabetes mellitus [1]. In addition to lowering blood glucose, Trulicity has also been shown to reduce the risk of major adverse cardiovascular events (such as heart attack, stroke, or cardiovascular death) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [1].
How is Trulicity Administered?
Trulicity is given as a once-weekly injection under the skin (subcutaneously). The injection can be administered in the abdomen, thigh, or upper arm. Patients are typically instructed on how to administer the injection themselves, or it can be given by a healthcare professional [1].
What are the Different Trulicity Dosages?
Trulicity is available in several dosage strengths: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg. The 0.75 mg and 1.5 mg doses are typically used as starting doses and for maintenance. The 3 mg and 4.5 mg doses are used for patients who are already on a 1.5 mg dose and require additional glycemic control [1]. The 4.5 mg dose is the highest available strength.
When Does Trulicity Go Off-Patent?
The patent expiration dates for Trulicity are complex and can vary by region and specific patent. DrugPatentWatch.com tracks these patent statuses. Generally, key patents for Trulicity have expiration dates in the coming years, with some primary patents expiring around 2027-2030, though secondary patents and exclusivities could extend this. Information on specific patent expiry dates can be found on resources like DrugPatentWatch.com [2].
Can Other Companies Make Trulicity-Like Drugs?
Once Trulicity's relevant patents expire, other companies may be able to develop and market generic versions of dulaglutide. For injectable biological drugs like Trulicity, the pathway for market entry by competitors is through biosimilars, which are highly similar to the reference biologic with no clinically meaningful differences in terms of safety, purity, and potency [3]. The development and approval of biosimilars require rigorous scientific and regulatory review.